Jacobs Levy Equity Management Inc. raised its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 58.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 237,511 shares of the company's stock after purchasing an additional 87,830 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.52% of Y-mAbs Therapeutics worth $1,052,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of the business. Northern Trust Corp lifted its holdings in shares of Y-mAbs Therapeutics by 6.5% in the 4th quarter. Northern Trust Corp now owns 359,223 shares of the company's stock valued at $2,813,000 after buying an additional 21,936 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Y-mAbs Therapeutics by 53.1% in the 1st quarter. Wellington Management Group LLP now owns 204,052 shares of the company's stock valued at $904,000 after buying an additional 70,789 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 869.3% in the 1st quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock valued at $730,000 after buying an additional 147,788 shares during the period. Infinitum Asset Management LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at approximately $1,218,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Y-mAbs Therapeutics by 223.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 155,522 shares of the company's stock valued at $689,000 after buying an additional 107,511 shares during the period. 70.85% of the stock is owned by institutional investors and hedge funds.
Y-mAbs Therapeutics Stock Performance
Y-mAbs Therapeutics stock remained flat at $8.61 during trading on Wednesday. The company has a market cap of $391.24 million, a PE ratio of -17.22 and a beta of 0.54. The business's 50 day simple moving average is $7.10 and its two-hundred day simple moving average is $5.44. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $16.11.
Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.20. The company had revenue of $19.52 million during the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%. Equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.
Analysts Set New Price Targets
YMAB has been the subject of several recent analyst reports. Wedbush cut Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and set a $8.60 price target for the company. in a report on Tuesday, August 5th. Jones Trading cut Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Canaccord Genuity Group cut Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price objective for the stock from $26.00 to $8.60 in a report on Tuesday, August 5th. HC Wainwright reaffirmed a "neutral" rating and set a $8.60 price objective (down from $11.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, August 6th. Finally, Truist Financial set a $8.60 price objective on Y-mAbs Therapeutics in a report on Tuesday, August 5th. Eight analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and a consensus price target of $9.62.
Check Out Our Latest Stock Report on Y-mAbs Therapeutics
About Y-mAbs Therapeutics
(
Free Report)
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Featured Articles

Before you consider Y-mAbs Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Y-mAbs Therapeutics wasn't on the list.
While Y-mAbs Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.